Chlamydia Market Growth Forecast With Analysis Of Industry Progress Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Chlamydia Market By 2030 Based On Its 2026 Value?

The chlamydia market has experienced robust growth in recent years. It is projected to expand from $3.23 billion in 2025 to $3.51 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. This historical growth can be ascribed to several factors, including the increasing prevalence of sexually transmitted infections, the broadening of public health screening programs, enhanced access to diagnostic laboratories, greater awareness of reproductive health, and the widespread availability of antibiotic treatment options.

The chlamydia market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach $4.86 billion, exhibiting a compound annual growth rate (CAGR) of 8.5%. This projected growth is driven by several factors, including the escalating demand for point-of-care diagnostics, a heightened emphasis on preventive sexual healthcare, the proliferation of digital health screening platforms, increasing capital allocation to diagnostic innovation, and the expansion of government-initiated STI control programs. Key trends anticipated during this period encompass the wider acceptance of rapid chlamydia testing, a surge in the application of NAAT-based diagnostic techniques, a stronger commitment to early STI screening initiatives, the development of home-based testing solutions, and greater public understanding of asymptomatic infections.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21138&type=smp

What Important Drivers Are Powering The Chlamydia Market Growth?

A rising incidence of sexually transmitted diseases is projected to boost the expansion of the chlamydia market in the future. Sexually transmitted diseases (STDs) are defined as infections transmitted via sexual contact, encompassing conditions such as chlamydia, gonorrhea, and HIV. This uptick in STDs is linked to several elements like reduced condom utilization, insufficient public awareness, restricted access to healthcare services, and the widespread use of dating applications promoting numerous sexual partners. Treating chlamydia plays a role in curbing the dissemination of STDs by eradicating the infection, averting potential complications, and diminishing the likelihood of passing it on to sexual partners. For example, in October 2025, the Minority HIV/AIDS Fund (MHAF), an US-based government agency, reported that an estimated 39.9 million individuals worldwide were living with HIV in 2023, including 38.6 million adults and 1.4 million children, a higher figure compared to previous years. Consequently, the rising occurrence of sexually transmitted diseases is fueling the expansion of the chlamydia market.

What Key Segment Areas Are Included In The Chlamydia Market Assessment?

The chlamydia market covered in this report is segmented –

1) By Test Type: Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, Other Test Types

2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration

3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Culture Tests: Urethral Swab Culture, Endocervical Swab Culture, Urine Culture Test, Conjunctival Swab Culture

2) By Nucleic Acid Amplification Test (NAAT): PCR (Polymerase Chain Reaction), Transcription-Mediated Amplification (TMA), Strand Displacement Amplification (SDA), Loop-Mediated Isothermal Amplification (LAMP)

3) By Direct Fluorescent Antibody Test: DFA Test For Urogenital Chlamydia, DFA Test For Ocular Chlamydia, DFA For Respiratory Chlamydia Detection

4) By Serology Tests: Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence Assay (IFA), Western Blot

5) By Other Test Types: Immunochromatographic Rapid Test, Lateral Flow Immunoassay, Hybrid Capture Test (HCT)

What Trends Are Influencing The Chlamydia Market Outlook?

Leading companies within the chlamydia market are concentrating on creating advanced solutions, particularly expanding point-of-care molecular diagnostics, to facilitate quicker, more precise detection at the site of care and enhance prompt treatment results. This expansion signifies a wider acceptance of swift, on-location molecular tests, which enable the immediate identification of infections, including chlamydia, eliminating the need for central laboratory processing. As an illustration, in January 2025, F. Hoffmann-La Roche AG, a healthcare firm based in Switzerland, secured both FDA 510(k) clearance and a CLIA waiver for its cobas liat molecular tests, specifically engineered for point-of-care diagnosis of sexually transmitted infections (STIs). These particular tests feature multiplex assay panels capable of identifying and distinguishing several STIs, including chlamydia, gonorrhea, and Mycoplasma genitalium, all from one patient sample, providing results within 20 minutes or even faster.

Which Firms Are Competing In The Chlamydia Market?

Major companies operating in the chlamydia market are Siemens Healthineers, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Hologic Inc, Quidel Corporation, Bio-Rad Laboratories Inc, Ortho Clinical Diagnostics, DiaSorin SpA, Eiken Chemical Co Ltd, MedMira Inc, GenMark Diagnostics Inc, ACON Laboratories Inc, Biocartis Group NV, Inova Diagnostics Inc, Trinity Biotech Plc, Seegene Inc, Qiagen NV, Binx Health Inc, Chembio Diagnostics Inc, Visby Medical Inc.

Access The Complete Chlamydia Market Report:

https://www.thebusinessresearchcompany.com/report/chlamydia-global-market-report

Which Regional Market Leads The Chlamydia Market?

North America was the largest region in the chlamydia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Chlamydia Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21138&type=smp

Browse Through More Reports Similar to the Global Chlamydia Market 2026, By The Business Research Company

Sciatica Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/sciatica-global-market-report

Physical Therapy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/physical-therapy-global-market-report

Homeopathy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/homeopathy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795